RxDoctor Payments Data

Ahmad Aswad

Critical Care Medicine · Miami, FLNPI 1194956987

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,529 of the $3,084 with a category attached, or 82.0%. Astrazeneca UK Limited accounts for 62.5% of it on its own, with 2 other manufacturers making up the rest.

$3,084in general payments, 2019–2025

Across 18 payments — averaging $171.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$2K
  • Eisai Inc.$1K
  • Alkermes, Inc.$21
$6,555,893in research payments, 2019–2025

Across 2,226 payments — averaging $2945.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$4.2M
  • Akebia Therapeutics Inc$2.4M

What the payments were for

  • Travel & lodging$2,52982%
  • Food & beverage$55618%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited8$1,927
Eisai Inc.9$1,136
Alkermes, Inc.1$21

How this compares

$3,084 in reported general payments places this provider in the 85th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Other critical care medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →